Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026
Management Insights: Humacyte, Inc. reported a successful commercial launch of Symvess, with 45 hospitals evaluating the product and five already approving purchases, while also implementing cost reductions to extend their cash runway amidst a challenging economic environment.
Financial Performance: The company recorded $517,000 in revenue for Q1 2025, marking its first commercial sales, alongside significant cost savings initiatives expected to yield approximately $13.8 million in net savings for the year.
Trade with 70% Backtested Accuracy
Analyst Views on HUMA
About HUMA
About the author
BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their market endeavors.
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
